Renaissance Capital logo

edit News

Bigger and better: 2016 IPOs that raised more than $100 million are up over 30%

TWLO

The 21 IPOs this year that have raised raised over $100 million have delivered investors an average return of 32%, including a first-day pop of 14% and an additional 14% in the aftermarket. Most notably, only one IPO in this group currently trades below issue, biotech Hutchison China MediTech (HCM). Top-performers are fast-growing tech companies...read more

Gene editing biotech Intellia Therapeutics files for a $120 million IPO

NTLA

Intellia Therapeutics, which is developing gene editing therapies using CRISPR/Cas9 technology, filed on Monday with the SEC to raise up to $120 million in an initial public offering. Fellow CRISPR gene editing biotech Editas Medicine (EDIT) went public in February with significant insider buying, and currently trades 137% above its offer price. The Cambridge , MA-based...read more

Renaissance Capital's 1Q16 US IPO Market Review

EDIT

The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing shareholders. The resulting low tradable float also helped to prop up performance, and IPOs averaged a return of 25%, even...read more

Biotechs lean heavily on insider buying to complete quasi-IPOs

AVXS

Accounting for 100% of the four IPOs so far this year, biotechs appeared to be the one sector able to generate demand from public investors. But demand is weaker than it seems. Of the nearly $400 million raised, insiders publicly indicated on 31% of proceeds, which is about 50% higher than...read more